Ranbaxy gets tentative US okay for generic allergy drug

May 17 (Reuters) - India-based Ranbaxy Laboratories Ltd.'s (RANB.BO) U.S. unit said it received tentative regulatory approval to market generic Fexofenadine Hydrochloride tablets for seasonal allergic rhinitis.

Ranbaxy said the U.S. regulators have tentatively approved 30 mg, 60 mg, and 180 mg dosages of the tablet.

(Reporting by Jennifer Robin Raj in Bangalore)

((Editing by Anil Kumar; Reuters Messaging: aruna.jennifer.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: RANBAXY APPROVAL/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS1810